Shengguang Wang

Mr. Shengguang Wang

,

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
SWShengguang Wang
Shengguang Wang
SZShiming Zhang
Shiming Zhang
SWshaoping wang
shaoping wang
Peng GaoPeng Gao
Peng Gao
LDLong Dai
Long Dai
Pueraria species are listed in the Chinese Pharmacopeia and are being used for the treatment of various health ailments and in protecting health. Puerarin, a chemotaxonomic marker of Pueraria, received investigational drug status for the treatment of alcohol abuse and listed in DRUGBANK database. The purpose of this review is to provide insights on health benefits of Pueraria, its bioactive constituents and molecular mechanisms. The information is retrieved from various databases. The most investigated plant part is tuber and the major bioactive constituents are isoflavones. The Pueraria is reported to possess a lots of health benefits on brain, liver, heart, kidney, bone, stomach, muscle, skin, and reproductive system. Pueraria also shown beneficial effects in postmenopausal women. In this review, the scientific information on Pueraria reported until May 2020 were analysed and summarized logically to appreciate its health benefits and to identify research gaps.

15 February 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YWYumin Wei
Yumin Wei
YLYanan Li
Yanan Li
SWShengguang Wang
Shengguang Wang
ZXZedong Xiang
Zedong Xiang
XLXiaoyu Li
Xiaoyu Li
LDLong Dai
Long Dai

24 October 2022 in Molecules
Verified
Journal Article
Open access
PDF file
ZLZhen Li
Zhen Li
SWShengguang Wang
Shengguang Wang
XWXinyu Wang
Xinyu Wang
PGPeng Gao
Peng Gao
SZShiming Zhang
Shiming Zhang
LDLong Dai
Long Dai
Herb–drug interactions are vital in effectively managing type-2-diabetes complications. Puerarin is a natural isoflavonoid in the Pueraria genus, and its pharmacological activities, including antidiabetic activity, are well established. The similar modes of action of puerarin and metformin in diabetic models suggest their positive pharmacodynamic interactions. This study investigated this in streptozotocin/nicotinamide-induced type-2 diabetic rats. Puerarin at doses of 80 mg/kg, 120 mg/kg and 160 mg/kg improved the activity of metformin in reversing hyperglycaemia, dysregulated lipid profiles, dysfunction of the liver, kidney, and pancreas, and inflammation. The treatment with either puerarin (high dose, 160 mg/kg intraperitoneally) or metformin (100 mg/kg intraperitoneally) did not bring the dysregulated biomarkers to normal levels in 4 weeks. By contrast, the combination of puerarin (160 mg/kg) and metformin (100 mg/kg) did. This study is the first to report scientific evidence for the positive pharmacodynamic interactions between puerarin and metformin.